'Trials For Nasal Covid Vaccine Slated For November'

"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1548839_1_20200910182024.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1548839-20200910.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1548839-20200910.htm', 'DCS.dcsqry', '' ); } } }); }); });
2020-09-10 HKT 11:42
Hong Kong University microbiologist Professor Yuen Kwok-yung said they hope to start clinical trials for a new nasal spray vaccine for Covid-19 in November.
Yuen, who is the chair of infectious diseases at the university's department of microbiology, made the comments after HKU announced that mainland authorities had given the go ahead for clinical trials for the nasal spray – which it has been developing with some mainland institutions.
Speaking on a Commercial Radio programme, Yuen said that the university has received funding of about HK$20 million from the authorities, and they hope to recruit about 100 healthy people in Hong Kong for the trials.
He said that vaccine development requires three phases of clinical trials, and after the launch of phase one this year, it will take about one more year at the earliest before the vaccine can be used.
HKU's State Key Laboratory of Emerging Infectious Diseases has been working on the vaccine with Xiamen University and Beijing Wantai Biological Pharmacy.
Yuen said that since Hong Kong does not have its own facilities for developing vaccines, it needs to cooperate with the mainland.
HKU said their vaccine is so far the only nasal spray vaccine against the coronavirus to be approved by the National Medical Products Administration for clinical trials.
Future Fintechs Hong Kong Subsidiary Seeks VASP And Asset Management Licenses
Future Fintech, a financial and digital technology services provider, announced that its wholly owned Hong Kong subsidi... Read more
Can Regulation Scale With Innovation? Inside The Stablecoin Plans Of HK And The U.S.
Back in 2022, stablecoins were still an emerging topic. Yet, they stirred enough flurry for the Hong Kong Monetary Auth... Read more
Cyberport Start-ups Forge Regional Fintech Ties At MyFintech Week 2025 In Malaysia
Cyberport led a delegation of its fintech start-ups to MyFintech Week 2025 (MyFW 2025), held in Kuala Lumpur from 4 to ... Read more
Hong Kongs Stablecoin Law Triggers Industry Concerns Over KYC Rules
Hong Kong’s newly implemented stablecoin law, in effect since 1 August, has sparked concern among some in the industr... Read more
Stopping Fraud At The Gate: The New Imperative For Registration & Transaction Monitoring
The Asia-Pacific fintech landscape is thriving, fueled by the rapid adoption of digital payments, online banking and al... Read more
Hong Kong Private Banks See 14% Growth, Hire 400 More Wealth Managers
Hong Kong’s private banking and wealth management sectors are poised for further growth in hiring and office expansio... Read more